TE与TEC新辅助化疗方案对乳腺癌患者外周血CTCs及TSCs的影响

摘要

Objective: To analyze the effect of TE and TEC neoadjuvant chemotherapy on CTCs and TSCs in peripheral blood of patients with breast cancer. Methods: 155 cases of patients with breast cancer were selected from January 2015 to June 2016 in our hospital. The patients were divided into control group ( 77 cases) and observation group (78 cases) according to the random number table method. The patients in con-trol group were treated with TE regimen, the observation group received TEC regimen, the curative effect, ad-verse reaction, CTCs and TSCs level in the two groups were observed. Results: Compared with the control group, the effective rate of the observation group was 89.7%, the difference was not significant (χ2=0.932, P>0.05) , the neutrophils in the observation group were significantly more, the difference was significant (χ2=8.923,P<0.05) , but there was no significant difference in gastrointestinal tract reaction, cardiotoxicity, liver function abnormality, thrombocytopenia, alopecia and serum albumin (P>0.05). Compared with the control group, there was no significant difference in CTCs level between the observation group and the control group (χ2=1.293, 1.441, 0.992, P>0.05). There was no significant difference in TSCs between the two groups (χ2=1.903, 1.783, P>0.05) , but the level of TSCs in stageⅢwas significantly lower than that in stageⅢ(χ2= 7.543, P<0.05). Conclusion: The TE and TEC neoadjuvant chemotherapy for breast cancer patients with similar clinical efficacy, TEC program to reduce stage Ⅲ breast cancer patients with peripheral blood TSCs may be better than the TE program.%目的:探讨多西他赛+表柔比星(TE)与多西他赛+吡柔比星+环磷酰胺(TEC)新辅助化疗方案对乳腺癌患者外周血循环肿瘤细胞(circulating tumor cells,CTCs)及肿瘤干细胞(Tumor stem cells,TSCs)的影响.方法:选取2015年1月至2016年6月收入我院的155例女性原发性乳腺癌患者,根据随机数字表法分为对照组77例,观察组78例.对照组接受TE方案治疗;观察组接受TEC方案治疗,观察两组患者的疗效、不良反应、外周血CTCs及TSCs水平.结果:与对照组相比,观察组患者的有效率为89.7%,对比后,差异不显著(χ2=0.932,P>0.05),与对照组相比,观察组患者中性粒细胞较对照组显著增高,差异有统计学意义(χ2=8.923,P<0.05),而胃肠道反应、心脏毒性、肝功能异常、血小板减少、脱发及血蛋白方面并无统计学意义(P>0.05).与对照组患者相比,观察组治疗后Ⅰ期、Ⅱ期、Ⅲ期患者的外周血CTCs水平差异不显著(χ2=1.293、1.441、0.992,P>0.05),观察组治疗后Ⅰ期、Ⅱ期患者的外周血TSCs对比后,差异不显著(χ2=1.903、1.783,P>0.05),而Ⅲ期患者的外周血TSCs明显更低,对比后,差异显著(χ2=7.543,P<0.05).结论:TE与TEC两种新辅助化疗方案对乳腺癌患者的临床效果相近,TEC方案降低Ⅲ期乳腺癌患者的外周血TSCs的效果可能优于TE方案.